[1]Pietro L,Massimo C. Nucleos(t)ide analog therapy of chronic hepatitis B and liver cancer riskreduction: better nucleotides than nucleosides. Gastroenterology,2019,157(6):1682-1684. [2]田贤江,赵立夫,沈跃飞,等. 恩替卡韦治疗HBV DNA低水平HBeAg阳性慢性乙型肝炎可抑制病毒复制及改善肝组织学病变. 中华临床感染病杂志,2019,12(2):107-110. [3]Liem K S,Van Campenhout M J H,Xie Q,et al. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther,2019,49(4):448-456. [4]刘如玉,李明慧,谢尧,等. HBeAg阴性初治慢乙型肝炎患者恩替卡韦4年抗病毒治疗FIB-4评分动态变化研究. 中华实验和临床病毒学杂志,2020,34(1):51-56. [5]Zhang D,Wang Y,Zhang H Y,et al. Histone deacetylases and acetylated histone H3 are involved in the process of hepatitis B virus DNA replication. Life Sci,2019,223(15):1-8. [6]Liu Y,Feng J,Sun M,et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett,2019,454(29):16-19. [7]Chen E Q,Wang M L,Tao Y C,et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat,2019,26(5):586-595. [8]Yanpin M,Xuli B,Fang X,et al. The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy. Cell Mol Biol,2019,65(2):75-81. [9]中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32. [10] 谢知兵,周建亮,于红缨,等. HBV前基因组RNA检测在乙型肝炎治疗中的临床研究. 中华医院感染学杂志,2020,19(5):26-29. [11] 王颖,赵奎,秦建忠. HBV cccDNA,HBsAg,HBV pgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值. 临床肝胆病杂志,2020, 36(5):57-62. [12] 蒋贝,刘畅,苏瑞,等. 血清HBV RNA在HBeAg阴性慢性乙型肝炎患者中的检测价值. 中华肝脏病杂志,2019,27(9):668-672. [13] Nkongolo S, Nubaum L,Lempp FA,et al. The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA. Antiviral Res,2019,168(12):146-155. [14] 饶希,施欢欢,吴振平,等. 长期核苷酸类似物治疗的慢性乙型肝炎患者血清HBV pgRNA与抗原状态变化的相关性研究.中华肝脏病杂志,2021,29(8):766-770. [15] Lin N,Ye A,Lin J,et al. Diagnostic value of serum pgRNA detection in HBV-infected patients with different clinical outcomes. J Clin Microbiol,2019,58(2):24-26. [16] 鲁凤民,王杰,陈香梅,等. 新型血清指标在乙型肝炎创新药物研发中的应用. 中华肝脏病杂志,2020,28(8):649-653. [17] 缪晓辉,裴彬,周璐靖. 核苷类药物抗HBV治疗安全停药的预测指标. 中华传染病杂志,2019,37(12):707-710. [18] 扆琳珠,史晓红,王丹丹,等. HBsAg阳性母亲PBMC HBV cccDNA对新生儿Th1/Th2型细胞因子的影响. 中华疾病控制杂志,2019,23(6):700-705. [19] Liu Y,Feng J,Sun M,et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett,2019,454(29):158-170. [20] 谢知兵,周建亮,于红缨,等. HBV前基因组RNA检测在乙型肝炎治疗中的临床研究. 中华医院感染学杂志,2020,30(5):693-697. [21] Carey I, Gersch J,Wang B,et al. Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology,2020,72(1):42-57. |